Last reviewed · How we verify
Administration of Vorolanib
Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) to inhibit angiogenesis and tumor growth.
Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) to inhibit angiogenesis and tumor growth. Used for Advanced or metastatic solid tumors (Phase 2 investigation).
At a glance
| Generic name | Administration of Vorolanib |
|---|---|
| Sponsor | Li-kun Chen |
| Drug class | VEGFR tyrosine kinase inhibitor |
| Target | VEGFR (vascular endothelial growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Vorolanib works by blocking VEGFR signaling pathways, which are critical for new blood vessel formation that tumors depend on for growth and metastasis. By inhibiting these receptors, the drug starves tumors of their blood supply while also potentially having direct anti-proliferative effects on cancer cells. This mechanism is typical of anti-angiogenic small molecule kinase inhibitors used in oncology.
Approved indications
- Advanced or metastatic solid tumors (Phase 2 investigation)
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Proteinuria
- Hand-foot skin reaction
Key clinical trials
- Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (PHASE2)
- Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI (PHASE3)
- Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma (PHASE2)
- Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study (PHASE2)
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (PHASE1, PHASE2)
- A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma (NA)
- Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of Vorolanib CI brief — competitive landscape report
- Administration of Vorolanib updates RSS · CI watch RSS
- Li-kun Chen portfolio CI